Boston, MA 02\/20\/2014 (wallstreetpr) –\u00a0Pfizer Inc. (NYSE:PFE)<\/b> has three out of six late-stage drugs intended for cancer treatments and this reveals the new strategy that the company has recently adopted. Of late PFE is seen channeling or trying to channel resources into oncology and immunology instead of cardiovascular. Perhaps the reason behind this is that cancer is a key growth area compared to cardiovascular that is already flooded with generics. But even as PFE turns attention to cancer treatment, we can expect the company to trim its research and development spending due to reduced focus on cardiovascular activities. Pfizer needs fresh revenue opportunities as its legacy drugs decline in revenue. Shares of Pfizer Inc. (NYSE:PFE) lost 40 cents each in the last session, and ended up the day south at $31.48 per share.<\/p>\n
The Coca-Cola Company (NYSE:KO) <\/b>will boost its marketing and media investment by up to $1 billion by 2016, the company\u2019s CEO Muhtar Kent said. This revelation comes just when it emerged that the Sprite-maker was facing shrinking sales in North America, while emerging markets growth was in a slowdown. While analysts have since questioned if indeed the answer to KO\u2019s woes lies in boosting marketing campaigns, the company seems to be content that increasing spending on advertisement will work best towards boosting performance. Now, The Coca-Cola Company (NYSE:KO) is looking to cost-cutting as a means to raise the extra money needed to funded increased advertisement spending. The stock price of KO dipped in the last session, losing 37 cents per piece to close at $37.10 per share.<\/p>\n
Intel Corporation (NASDAQ:INTC)<\/b> is turning greater focus on software. According to the company\u2019s CEO Brian Krzanich, there is perhaps greater need for software now than ever before. The company has of late been investing on software acquisition and intends to push its way into PC, sever, tablets and mobile markets. Perhaps the latest plans mean that it would no longer be possible to just unbox and fix Intel chips as it used to be in the earlier days. Intel Corporation (NASDAQ:INTC) lost 26 cents per share to close at $24.50 per share in the last session.<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 02\/20\/2014 (wallstreetpr) –\u00a0Pfizer Inc. (NYSE:PFE) has three out of six late-stage drugs intended for cancer treatments and this reveals the new strategy that […]<\/p>\n","protected":false},"author":6,"featured_media":15630,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[1900,597,1670,993,2745,2760],"stock_ticker":[],"class_list":["post-15629","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-intel-corporation-nasdaqintc","tag-nasdaqintc","tag-nyseko","tag-nysepfe","tag-pfizer-inc-nysepfe","tag-the-coca-cola-company-nyseko","entry"],"acf":[],"yoast_head":"\n